Anti-MMP2/ MMP-2/ CLG4 monoclonal antibody

Anti-MMP2/ MMP-2/ CLG4 antibody for FACS & in-vivo assay

Target products collectionGo to MMP-2/MMP2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T68251-Ab-1/ GM-Tg-hg-T68251-Ab-2Anti-Human MMP-2/MMP2 monoclonal antibodyHuman
GM-Tg-rg-T68251-Ab-1/ GM-Tg-rg-T68251-Ab-2Anti-Rat MMP-2/MMP2 monoclonal antibodyRat
GM-Tg-mg-T68251-Ab-1/ GM-Tg-mg-T68251-Ab-2Anti-Mouse MMP-2/MMP2 monoclonal antibodyMouse
GM-Tg-cynog-T68251-Ab-1/ GM-Tg-cynog-T68251-Ab-2Anti-Cynomolgus/ Rhesus macaque MMP-2/MMP2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T68251-Ab-1/ GM-Tg-felg-T68251-Ab-2Anti-Feline MMP-2/MMP2 monoclonal antibodyFeline
GM-Tg-cang-T68251-Ab-1/ GM-Tg-cang-T68251-Ab-2Anti-Canine MMP-2/MMP2 monoclonal antibodyCanine
GM-Tg-bovg-T68251-Ab-1/ GM-Tg-bovg-T68251-Ab-2Anti-Bovine MMP-2/MMP2 monoclonal antibodyBovine
GM-Tg-equg-T68251-Ab-1/ GM-Tg-equg-T68251-Ab-2Anti-Equine MMP-2/MMP2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T68251-Ab-1/ GM-Tg-hg-T68251-Ab-2; GM-Tg-rg-T68251-Ab-1/ GM-Tg-rg-T68251-Ab-2;
GM-Tg-mg-T68251-Ab-1/ GM-Tg-mg-T68251-Ab-2; GM-Tg-cynog-T68251-Ab-1/ GM-Tg-cynog-T68251-Ab-2;
GM-Tg-felg-T68251-Ab-1/ GM-Tg-felg-T68251-Ab-2; GM-Tg-cang-T68251-Ab-1/ GM-Tg-cang-T68251-Ab-2;
GM-Tg-bovg-T68251-Ab-1/ GM-Tg-bovg-T68251-Ab-2; GM-Tg-equg-T68251-Ab-1/ GM-Tg-equg-T68251-Ab-2
Products NameAnti-MMP-2/MMP2 monoclonal antibody
Formatmab
Target NameMMP-2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MMP-2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species MMP2/ MMP-2/ CLG4 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLP001345human NM_004530humanNM_004530 Lentivirus plasmid
    ORF Viral VectorpGMAP000238Human MMP2 Adenovirus plasmid
    ORF Viral VectorvGMAP000238Human MMP2 Adenovirus particle
    ORF Viral VectorvGMLP001345human NM_004530humanNM_004530 Lentivirus particle
    ORF Viral VectorpGMAAV000161mouse Mmp2 AAV plasmid
    ORF Viral VectorvGMAAV000161mouse Mmp2 AAV particle


    Target information

    Target IDGM-T68251
    Target NameMMP-2
    Gene ID4313,17390,81686,698478,403733,101098838,282872,100033948
    Gene Symbol and SynonymsCLG4,CLG4A,GelA,MMP-2,MMP-II,MMP2,MONA,TBE-1
    Uniprot AccessionP08253,P33436,Q9GLE5
    Uniprot Entry NameMMP2_HUMAN,MMP2_RAT,MMP2_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target
    DiseaseOvary Cancer, Neoplasm, Type 1 diabetes mellitus, Vesicoureteral reflux, Alport syndrome, Chronic Kidney Disease, Chronic tubulo-interstitial nephritis, Malignant neoplasm of bladder, Malignant neoplasms of female genital organs
    Gene EnsemblENSG00000087245
    Target ClassificationCheckpoint-Immuno Oncology

    The target: MMP-2, gene name: MMP2, also named as CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1. This gene is a member of the matrix metalloproteinase (MMP) gene family, that are zinc-dependent enzymes capable of cleaving components of the extracellular matrix and molecules involved in signal transduction. The protein encoded by this gene is a gelatinase A, type IV collagenase, that contains three fibronectin type II repeats in its catalytic site that allow binding of denatured type IV and V collagen and elastin. Unlike most MMP family members, activation of this protein can occur on the cell membrane. This enzyme can be activated extracellularly by proteases, or, intracellulary by its S-glutathiolation with no requirement for proteolytical removal of the pro-domain. This protein is thought to be involved in multiple pathways including roles in the nervous system, endometrial menstrual breakdown, regulation of vascularization, and metastasis. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.